751 related articles for article (PubMed ID: 23442071)
1. Targeted modifications in adeno-associated virus serotype 8 capsid improves its hepatic gene transfer efficiency in vivo.
Sen D; Gadkari RA; Sudha G; Gabriel N; Kumar YS; Selot R; Samuel R; Rajalingam S; Ramya V; Nair SC; Srinivasan N; Srivastava A; Jayandharan GR
Hum Gene Ther Methods; 2013 Apr; 24(2):104-16. PubMed ID: 23442071
[TBL] [Abstract][Full Text] [Related]
2. Bioengineering of AAV2 capsid at specific serine, threonine, or lysine residues improves its transduction efficiency in vitro and in vivo.
Gabriel N; Hareendran S; Sen D; Gadkari RA; Sudha G; Selot R; Hussain M; Dhaksnamoorthy R; Samuel R; Srinivasan N; Srivastava A; Jayandharan GR
Hum Gene Ther Methods; 2013 Apr; 24(2):80-93. PubMed ID: 23379478
[TBL] [Abstract][Full Text] [Related]
3. Site-Directed Mutagenesis of Surface-Exposed Lysine Residues Leads to Improved Transduction by AAV2, But Not AAV8, Vectors in Murine Hepatocytes In Vivo.
Li B; Ma W; Ling C; Van Vliet K; Huang LY; Agbandje-McKenna M; Srivastava A; Aslanidi GV
Hum Gene Ther Methods; 2015 Dec; 26(6):211-20. PubMed ID: 26421998
[TBL] [Abstract][Full Text] [Related]
4. K137R mutation on adeno-associated viral capsids had minimal effect on enhancing gene delivery in vivo.
Qiao C; Li C; Zhao C; Li J; Bian T; Grieger J; Li J; Samulski RJ; Xiao X
Hum Gene Ther Methods; 2014 Feb; 25(1):33-9. PubMed ID: 24116972
[TBL] [Abstract][Full Text] [Related]
5. Improved adeno-associated virus (AAV) serotype 1 and 5 vectors for gene therapy.
Sen D; Balakrishnan B; Gabriel N; Agrawal P; Roshini V; Samuel R; Srivastava A; Jayandharan GR
Sci Rep; 2013; 3():1832. PubMed ID: 23665951
[TBL] [Abstract][Full Text] [Related]
6. Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold?
Aslanidi GV; Rivers AE; Ortiz L; Song L; Ling C; Govindasamy L; Van Vliet K; Tan M; Agbandje-McKenna M; Srivastava A
PLoS One; 2013; 8(3):e59142. PubMed ID: 23527116
[TBL] [Abstract][Full Text] [Related]
7. Application of polyploid adeno-associated virus vectors for transduction enhancement and neutralizing antibody evasion.
Chai Z; Sun J; Rigsbee KM; Wang M; Samulski RJ; Li C
J Control Release; 2017 Sep; 262():348-356. PubMed ID: 28789965
[TBL] [Abstract][Full Text] [Related]
8. Optimized adeno-associated virus (AAV)-protein phosphatase-5 helper viruses for efficient liver transduction by single-stranded AAV vectors: therapeutic expression of factor IX at reduced vector doses.
Jayandharan GR; Zhong L; Sack BK; Rivers AE; Li M; Li B; Herzog RW; Srivastava A
Hum Gene Ther; 2010 Mar; 21(3):271-83. PubMed ID: 19788390
[TBL] [Abstract][Full Text] [Related]
9. Efficient Gene Delivery and Expression in Pancreas and Pancreatic Tumors by Capsid-Optimized AAV8 Vectors.
Chen M; Maeng K; Nawab A; Francois RA; Bray JK; Reinhard MK; Boye SL; Hauswirth WW; Kaye FJ; Aslanidi G; Srivastava A; Zajac-Kaye M
Hum Gene Ther Methods; 2017 Feb; 28(1):49-59. PubMed ID: 28125909
[TBL] [Abstract][Full Text] [Related]
10. Characterization of the relationship of AAV capsid domain swapping to liver transduction efficiency.
Shen X; Storm T; Kay MA
Mol Ther; 2007 Nov; 15(11):1955-62. PubMed ID: 17726459
[TBL] [Abstract][Full Text] [Related]
11. Chimeric Capsid Proteins Impact Transduction Efficiency of Haploid Adeno-Associated Virus Vectors.
Chai Z; Zhang X; Dobbins AL; Frost EA; Samulski RJ; Li C
Viruses; 2019 Dec; 11(12):. PubMed ID: 31835440
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of engineered AAV capsids for hepatic factor IX gene transfer in murine and canine models.
Markusic DM; Nichols TC; Merricks EP; Palaschak B; Zolotukhin I; Marsic D; Zolotukhin S; Srivastava A; Herzog RW
J Transl Med; 2017 May; 15(1):94. PubMed ID: 28460646
[TBL] [Abstract][Full Text] [Related]
13. Employing a gain-of-function factor IX variant R338L to advance the efficacy and safety of hemophilia B human gene therapy: preclinical evaluation supporting an ongoing adeno-associated virus clinical trial.
Monahan PE; Sun J; Gui T; Hu G; Hannah WB; Wichlan DG; Wu Z; Grieger JC; Li C; Suwanmanee T; Stafford DW; Booth CJ; Samulski JJ; Kafri T; McPhee SW; Samulski RJ
Hum Gene Ther; 2015 Feb; 26(2):69-81. PubMed ID: 25419787
[TBL] [Abstract][Full Text] [Related]
14. The threefold protrusions of adeno-associated virus type 8 are involved in cell surface targeting as well as postattachment processing.
Raupp C; Naumer M; Müller OJ; Gurda BL; Agbandje-McKenna M; Kleinschmidt JA
J Virol; 2012 Sep; 86(17):9396-408. PubMed ID: 22718833
[TBL] [Abstract][Full Text] [Related]
15. Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector.
Bowles DE; McPhee SW; Li C; Gray SJ; Samulski JJ; Camp AS; Li J; Wang B; Monahan PE; Rabinowitz JE; Grieger JC; Govindasamy L; Agbandje-McKenna M; Xiao X; Samulski RJ
Mol Ther; 2012 Feb; 20(2):443-55. PubMed ID: 22068425
[TBL] [Abstract][Full Text] [Related]
16. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy.
Gao GP; Alvira MR; Wang L; Calcedo R; Johnston J; Wilson JM
Proc Natl Acad Sci U S A; 2002 Sep; 99(18):11854-9. PubMed ID: 12192090
[TBL] [Abstract][Full Text] [Related]
17. Long-Term Follow-Up of the First in Human Intravascular Delivery of AAV for Gene Transfer: AAV2-hFIX16 for Severe Hemophilia B.
George LA; Ragni MV; Rasko JEJ; Raffini LJ; Samelson-Jones BJ; Ozelo M; Hazbon M; Runowski AR; Wellman JA; Wachtel K; Chen Y; Anguela XM; Kuranda K; Mingozzi F; High KA
Mol Ther; 2020 Sep; 28(9):2073-2082. PubMed ID: 32559433
[TBL] [Abstract][Full Text] [Related]
18. Kinetics of adeno-associated virus serotype 2 (AAV2) and AAV8 capsid antigen presentation in vivo are identical.
He Y; Weinberg MS; Hirsch M; Johnson MC; Tisch R; Samulski RJ; Li C
Hum Gene Ther; 2013 May; 24(5):545-53. PubMed ID: 23534873
[TBL] [Abstract][Full Text] [Related]
19. CD8+ T cell recognition of epitopes within the capsid of adeno-associated virus 8-based gene transfer vectors depends on vectors' genome.
Wu TL; Li H; Faust SM; Chi E; Zhou S; Wright F; High KA; Ertl HC
Mol Ther; 2014 Jan; 22(1):42-51. PubMed ID: 24077034
[TBL] [Abstract][Full Text] [Related]
20. Cross-presentation of adeno-associated virus serotype 2 capsids activates cytotoxic T cells but does not render hepatocytes effective cytolytic targets.
Wang L; Figueredo J; Calcedo R; Lin J; Wilson JM
Hum Gene Ther; 2007 Mar; 18(3):185-94. PubMed ID: 17324107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
